Key Points Ken Griffin's Citadel increased its AbbVie stake by over 500% in the second quarter of 2026. AbbVie isn't cheap, but it has a strong drug portfolio and appears to have successfully moved past a major patent cliff. 10 stocks we like better than AbbVie › Wall Street likes to keep tabs on investors with strong track records, such as Ken Griffin, the founder of the hedge fund Citadel. The goal is to find clues that could help guide your own investment approach, with the legally required 13F filing a key source of information. The most recent 13F from Griffin's Citadel shows that he made a big, second-quarter investment in AbbVie (NYSE: ABBV) , increasing his stake by over 500%.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.